These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7200891)

  • 1. Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity.
    Morgan LR; Donley PJ; Harrison EF; Hunter HL
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):113-4. PubMed ID: 7200891
    [No Abstract]   [Full Text] [Related]  

  • 2. The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.
    Morgan LR; Donley PJ; Harrison EF; Hunter HL
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):71-4. PubMed ID: 7163814
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
    Slavik M; Saiers JH
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):62-5. PubMed ID: 6836328
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Holoye PY; Duelge J; Hansen RM; Ritch PS; Anderson T
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):66-71. PubMed ID: 6836329
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD; Munshi N; Einhorn LH; Loehrer PJ
    Cancer Invest; 1990; 8(2):269. PubMed ID: 2119246
    [No Abstract]   [Full Text] [Related]  

  • 6. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
    Loehrer PJ; Williams SD; Einhorn LH
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):72-5. PubMed ID: 6836331
    [No Abstract]   [Full Text] [Related]  

  • 8. Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer.
    Saiers JH; Slavik M
    Vet Hum Toxicol; 1981; 23(Suppl 1):12-4. PubMed ID: 6272470
    [No Abstract]   [Full Text] [Related]  

  • 9. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C; Steiner R; Viollier AF
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ifosfamide in the treatment of small cell carcinoma of the lung].
    Mukouda K; Morikawa E; Hasegawa K; Noumi K; Ohmura T; Mishima Y; Kawamoto M; Inagaki A; Kamitsuna A; Yamakido M; Nishimoto Y; Koyama T; Katsuta S
    Gan To Kagaku Ryoho; 1983 May; 10(5):1293-8. PubMed ID: 6307164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies with ifosfamide in patients with malignant lymphoma.
    Rodriguez V; Cabanillas F; Bodey GP; Freireich EJ
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):87-92. PubMed ID: 7163815
    [No Abstract]   [Full Text] [Related]  

  • 13. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Costanzi JJ; Morgan LR; Hokanson J
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):61-5. PubMed ID: 6298945
    [No Abstract]   [Full Text] [Related]  

  • 14. Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
    Harrison EF; Hawke JE; Hunter HL; Costanzi JJ; Morgan LR; Plotkin D; Tucker WG; Worrall PM
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):56-60. PubMed ID: 6298944
    [No Abstract]   [Full Text] [Related]  

  • 15. [Toxic-allergic lung edema following cyclophosphamide and ifosfamide therapy. Case report].
    Kehl A; Bergholz M; von Heyden HW; Nagel GA
    Onkologie; 1983 Apr; 6(2):84-6. PubMed ID: 6306532
    [No Abstract]   [Full Text] [Related]  

  • 16. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas.
    Loehrer PJ; Williams SD; Einhorn LH; Ansari R
    J Clin Oncol; 1985 Mar; 3(3):367-72. PubMed ID: 3973647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide: chemotherapy with new promise and new problems for the urologist.
    Watson RA
    Urology; 1984 Nov; 24(5):465-8. PubMed ID: 6495457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H; Schnitker J; Fichtner E
    MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
    Fosså SD; Talle K
    Cancer Treat Rep; 1980; 64(10-11):1103-8. PubMed ID: 6780190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide vs cyclophosphamide in cancer therapy.
    Weiss RB
    Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.